Yoko Furutake

CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer

Masayo Ukita, Junzo Hamanishi, Hiroyuki Yoshitomi et al. · JCI Insight · 2022 · 172 citations · Full text

Lymphoid Neoplasia, Cancer Immunosurveillance, T-regulatory Cell +12

PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma

Sachiko Kitamura, Ken Yamaguchi, Ryusuke Murakami et al. · Cancer Science · 2021 · 33 citations · Full text

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass

Tadahiro Shoji, Eriko Takatori, Yoko Furutake et al. · International Journal of Clinical Oncology · 2016 · 21 citations · Full text

YAP1 Suppression by ZDHHC7 Is Associated with Ferroptosis Resistance and Poor Prognosis in Ovarian Clear Cell Carcinoma

Yoko Furutake, Ken Yamaguchi, Koji Yamanoi et al. · Molecular Cancer Therapeutics · 2024 · 13 citations

Gemcitabine and docetaxel in a patient with primary ovarian leiomyosarcoma: a case report and review of literature

Yoko Furutake, Tomoyuki Fukagawa, Yasuko Suga et al. · International Cancer Conference Journal · 2017 · 12 citations · Full text

Tumoral Pathology, Primary Ovarian Leiomyosarcoma, Medicine +6